New business models for antibiotic innovation.


Journal Article (Review)

The increase in antibiotic resistance and the dearth of novel antibiotics have become a growing concern among policy-makers. A combination of financial, scientific, and regulatory challenges poses barriers to antibiotic innovation. However, each of these three challenges provides an opportunity to develop pathways for new business models to bring novel antibiotics to market. Pull-incentives that pay for the outputs of research and development (R&D) and push-incentives that pay for the inputs of R&D can be used to increase innovation for antibiotics. Financial incentives might be structured to promote delinkage of a company's return on investment from revenues of antibiotics. This delinkage strategy might not only increase innovation, but also reinforce rational use of antibiotics. Regulatory approval, however, should not and need not compromise safety and efficacy standards to bring antibiotics with novel mechanisms of action to market. Instead regulatory agencies could encourage development of companion diagnostics, test antibiotic combinations in parallel, and pool and make transparent clinical trial data to lower R&D costs. A tax on non-human use of antibiotics might also create a disincentive for non-therapeutic use of these drugs. Finally, the new business model for antibiotic innovation should apply the 3Rs strategy for encouraging collaborative approaches to R&D in innovating novel antibiotics: sharing resources, risks, and rewards.

Full Text

Cited Authors

  • So, AD; Shah, TA

Published Date

  • May 2014

Published In

Volume / Issue

  • 119 / 2

Start / End Page

  • 176 - 180

PubMed ID

  • 24646116

Pubmed Central ID

  • 24646116

Electronic International Standard Serial Number (EISSN)

  • 2000-1967

International Standard Serial Number (ISSN)

  • 0300-9734

Digital Object Identifier (DOI)

  • 10.3109/03009734.2014.898717


  • eng